- Wearable technology matches the accuracy of the gold-standard sweat test while eliminating nearly every logistical barrier that keeps the standard test out of reach for millions of families worldwide.
A pair of soft, flexible stickers smaller than a bandage may soon transform how doctors diagnose cystic fibrosis (CF) — and, in doing so, reach children who would otherwise never be tested in time.
A new study demonstrates that this wearable technology matches the accuracy of the gold-standard sweat test while eliminating nearly every logistical barrier that keeps the standard test out of reach for millions of families worldwide.
The stakes are difficult to overstate. Cystic fibrosis is a genetic disorder that progressively clogs the lungs and disrupts digestion, and when it goes undetected, the consequences are devastating.
“It has been estimated that about half of people with CF around the world have not been diagnosed. Without treatment, their life expectancy is less than 5 years of age,” said Susanna McColley, MD, a CF expert at Ann & Robert H. Lurie Children’s Hospital of Chicago, professor of pediatrics at Northwestern University Feinberg School of Medicine, and co-senior author of the study.
“This is in stark contrast to 66 years, which is the projected median age of survival with treatment in the US currently.”
That gap — between five years and sixty-six — is what makes the new technology more than a clever engineering demo. It is, in the most literal sense, a question of who gets to live.
The diagnosis bottleneck
To understand why a sticker matters, it helps to understand what a conventional sweat test demands. Diagnosing CF requires measuring chloride levels in sweat, because the same faulty protein that causes the disease — the cystic fibrosis transmembrane conductance regulator, or CFTR — also makes sweat abnormally salty.
The standard procedure involves stimulating sweat glands on a baby’s arm or leg with a small electrical current and a chemical called pilocarpine, collecting the sweat into a coiled plastic tube, and sending that sample to a laboratory for analysis.
The process is cumbersome. It requires specialised equipment, trained technicians, and a clinical infrastructure that exists almost exclusively inside accredited CF centres at major children’s hospitals. For a family living hours from the nearest such centre — or in a lower-income country where no accredited lab exists at all — the test might as well be on the moon.
Babies slip through the cracks. By the time symptoms become unmistakable, irreversible lung damage has already begun.
The new system, developed by the bioengineering team of John Rogers at Northwestern University’s Querrey Simpson Institute for Bioelectronics in close collaboration with the Lurie Children’s CF centre, collapses that entire workflow into two stickers and a smartphone.
How the system works
The technology, dubbed CF SWIFT (Cystic Fibrosis Sweat Wearable Iontophoretic Field Test), is elegantly self-contained. The first sticker is a soft stimulator unit: it uses a mild chemical agent and a tiny button battery to trigger localised sweating — the same iontophoresis principle as the standard test, but miniaturised onto a flexible patch that conforms gently to a baby’s delicate skin.
The second sticker, applied to the same spot, collects the sweat and contains colour-changing reagents that react to chloride ions.
Here the smartphone enters the picture. A custom app captures an image of the collection sticker and analyses shifts in color density to calculate chloride concentration. No lab equipment. No couriered vials. The entire procedure wraps up in under an hour, and the result is available on the spot.
“This latest paper is a real advance over our previous report in Science Translational Medicine, which showed that sweat chloride could be accurately measured on a sticker after sweat stimulation using current technology,” said John Rogers, co-senior author on the study.
“The new ‘CF SWIFT’ device is a complete self-contained system, including the soft stimulator unit, with a much larger population of children studied and proof of clinical accuracy in measuring chloride.”
The study enrolled 55 participants spanning ages from infancy to 21 years: three healthy volunteers and 52 people with CF or CF-related conditions. Each participant was tested using both the conventional laboratory sweat test and the new sticker-based system, allowing a direct head-to-head comparison.
The results were unambiguous. “We found a high correlation in the results between the two methods, which demonstrates that the new technology reliably reflects sweat chloride measurements used for diagnosis of CF,” McColley said.
In practical terms, the stickers agreed with the gold standard well enough to serve as a credible diagnostic tool — not a screening test that flags ambiguous cases for follow-up, but a method capable of delivering a definitive answer.
That distinction matters. Resource-limited settings often lack the infrastructure for multi-step diagnostic cascades. A test that can give a clear yes-or-no answer, without requiring a second visit or a distant referral, is precisely what makes community-level diagnosis feasible.
The road to the clinic
For all its promise, the CF SWIFT system is not yet available in clinics. McColley was careful to outline what comes next: “Before these sweat testing stickers become clinically available, however, we need to validate our findings in a multicentre study with younger infants, since most sweat tests in the US are performed in the first weeks of life. Of course, FDA approval will be necessary for clinical use.”
That emphasis on younger infants is not incidental. Newborn screening for CF is now universal across the United States, and the overwhelming majority of diagnostic sweat tests are performed in a baby’s first month.
If the stickers are going to serve as a viable alternative or complement to the standard test, they must be proven reliable in that exact population — tiny patients with low sweat volumes and skin that demands the gentlest possible interface. The soft, flexible design of the stickers is well suited to this challenge, but the clinical data must catch up to the engineering.
A multi-centre trial also addresses a subtler question: reproducibility. A device that works beautifully in the hands of a research team at a top academic medical center must also work when administered by a community health worker in a rural clinic.
That transition — from controlled study to real-world deployment — is where many promising medical technologies stumble. The simplicity of the sticker-and-smartphone design is a deliberate hedge against that risk.
The CF SWIFT system belongs to a broader wave of skin-interfaced wearable sensors emerging from the Rogers laboratory and others. These devices share a design philosophy: replace bulky, power-hungry instruments with soft, disposable patches that leverage the capabilities already present in a smartphone — its camera, its processor, its wireless connectivity.
This approach inverts the traditional model of medical technology diffusion. Instead of asking every clinic in the world to acquire expensive, specialised hardware, it offloads complexity onto software and manufacturing — both of which can be centralised and scaled.
The stickers themselves become a commodity, while the diagnostic intelligence lives in an app that can be updated over the air.
Cystic fibrosis is an ideal first target for this model. The biomarker is well validated (sweat chloride has been the diagnostic standard for decades), the unmet need is enormous (millions of undiagnosed cases worldwide), and the clinical benefit of early detection is unambiguous.
But the same platform logic — a stimulation patch, a sensing patch, smartphone readout — could in principle be adapted to other sweat-based diagnostics, from electrolyte monitoring in athletes to screening for metabolic disorders.